Peter Butler, MD, FACE has been hired as Executive Director and Head of Clinical Development for the abaloparatide program. Dr. Butler is board certified in both Internal Medicine as well as Endocrinology and had a fellowship in Endocrinology, Diabetes and Metabolism at the National Institute of Health (NIH) in Bethesda, Maryland. Prior to joining Radius, Peter was a Clinical Research Medical Director in bone therapeutics at Amgen and was acting Global Development Lead for denosumab. Peter will report to Chhaya Shah " Head of the abaloparatide product from a clinical, regulatory and supply chain point of view.